Drug-drug interactions arising from the use of liposomal vincristine in combination with other anticancer drugs.
Waterhouse
D N
DN
Department of Advanced Therapeutics, B.C. Cancer Agency, Vancouver, Canada. dwater@bccancer.bc.ca
Dos Santos
N
N
Mayer
L D
LD
Bally
M B
MB
D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000493:pharmacokinetics; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000493:pharmacokinetics*; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage / Q000493:pharmacokinetics*; D004337:Drug Carriers; D004339:Drug Compounding; D004347:Drug Interactions; D005260:Female; D006863:Hydrogen-Ion Concentration; D015255:Idarubicin / Q000493:pharmacokinetics; D008081:Liposomes; D051379:Mice; D014750:Vincristine / Q000008:administration & dosage / Q000493:pharmacokinetics*
D000903:Antibiotics, Antineoplastic; D000970:Antineoplastic Agents; D000972:Antineoplastic Agents, Phytogenic; D004337:Drug Carriers; D008081:Liposomes; D014750:Vincristine; D015255:Idarubicin